Journal

Clinical Cancer Research

1078-0432 · American Association for Cancer Research (AACR)

35 verified public works

Browse all journals →

Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More

2026 · 0 citations

Topoisomerase-Based CDH17 Antibody Drug Conjugates Overcome P-gp Resistance but Undergo Target Mediated Clearance in Colorectal Cancer

2026 · 0 citations

Progress in Clinical Care and Research for Li-Fraumeni Syndrome: Perspectives from the 7th Li-Fraumeni Syndrome Association REACH Symposium

2026 · 0 citations

Endotrophin is a circulating fibroinflammatory biomarker associated with treatment response in human metastatic ER+ breast cancer

2026 · 0 citations

Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion–Positive Lung Cancers: A Phase II Trial of Cabozantinib

2026 · 0 citations

Long-term outcomes of modified-intensity lenalidomide, bortezomib and dexamethasone (RVD-lite) in transplant-ineligible multiple myeloma: final report of a phase II trial.

2026 · 0 citations

A Phase II Study of Nivolumab and Ipilimumab with Radiation Therapy in Patients with Metastatic, Microsatellite Stable Colorectal Cancer

2026 · 0 citations

FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma

2026 · 0 citations

Longitudinal liquid biopsy and matched radiomic analysis indicated resistance mechanisms of patients with biliary tract cancer undergoing systemic treatment.

2026 · 0 citations

Correction: A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL)

2026 · 0 citations

AACR Cancer Progress Report 2026

2026 · 0 citations

Liquid Biopsy in Biliary Tract Cancer: When Tissue Is Not Enough

2026 · 0 citations

Phase I Trial of GPC3-Targeted TCR Fusion Construct, CT0180, in Patients with Advanced Hepatocellular Carcinoma

2026 · 0 citations

Investigation of a Prostate Cancer Radiation Response Signature in the Breast Cancer SweBCG91RT Randomized Trial

2026 · 0 citations

“SMAC”-Down for the Apoptosis-Restoring Drug, Xevinapant: What Does Its Story Reveal?

2026 · 0 citations

Preclinical Characterization of CLSP-1025, a First-in-Class, Mutation-Specific T-Cell Engager Targeting a Neoantigen Derived from a Common p53 Mutation

2026 · 0 citations

First-in-Human, Open-label, Single-Arm Phase I Study of [211At] meta -Astatobenzylguanidine in Patients with Pheochromocytoma or Paraganglioma

2026 · 0 citations

Long-term Follow-up of Third-generation Anti-CD30 CAR T-cell Therapy in Relapsed/Refractory CD30+ Lymphomas: A Single-Arm, Multicenter, Phase I/II Trial

2026 · 0 citations

Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)

2026 · 0 citations

Sex-Biased Immunity: The Hidden Variable in Immuno-oncology

2026 · 0 citations

Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma Is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool

2026 · 0 citations

Molecular Profiling of Tisotumab Vedotin–Treated Patients Identifies Immune Pathways Associated with Clinical Activity

2026 · 0 citations

Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer

2026 · 0 citations

Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer

2026 · 0 citations

HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma

2026 · 0 citations

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer

2026 · 0 citations

Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects

2026 · 0 citations

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2− Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial

2026 · 0 citations

The H63D Polymorphism in the HFE Gene Promotes Aggressive Disease Phenotypes in Pancreatic Ductal Adenocarcinoma

2026 · 0 citations

A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

2026 · 0 citations